Initiation of diuretics or calcium channel blockers on the top of renin-angiotensin system inhibitors on kidney outcome: which is better?

We appreciate the study performed by Faucon et  al.1 and have read it with great interest. The authors conducted a nationwide, well-matched cohort study involving 5875 patients with nondialysis chronic kidney disease (CKD) stage 3–5. The study found that using a diuretic rather than a calcium channel blocker on top of renin-angiotensin system inhibitor (RASi) might improve kidney outcomes (CKD progression) without compromising cardioprotection. RASi is widely recognized as the first-line antihypertensive drug for patients with CKD,2 but there is no optimal recommendation for the choice of second-line antihypertensive therapy, such as di uretics or calcium channel blockers, in CKD.
Source: Kidney International - Category: Urology & Nephrology Authors: Tags: Letter to the Editor Source Type: research